Clinical Pharmacology and Toxicity of Low Daily Administration of Oral Etoposide in Advanced Lung Cancer Patients
- 1 December 1991
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 31 (12) , 1155-1160
- https://doi.org/10.1002/j.1552-4604.1991.tb03689.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.Journal of Clinical Oncology, 1985
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.Journal of Clinical Oncology, 1985
- Etoposide—chemistry, preclinical and clinical pharmacologyCancer Treatment Reviews, 1982
- Etoposide salvage therapy for refractory germ cell tumors: an updateCancer Treatment Reviews, 1982
- Pharmacokinetics of VP16-213 given by different administration methodsCancer Chemotherapy and Pharmacology, 1982
- VP16-213 (Etoposide)Cancer Chemotherapy and Pharmacology, 1982
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIAActa Pathologica Microbiologica Scandinavica Section A Pathology, 1973